Optimal designs for population pharmacokinetic studies of oral artesunate in patients with uncomplicated falciparum malaria

<p>Abstract</p> <p>Background</p> <p>Currently, population pharmacokinetic (PK) studies of anti-malarial drugs are designed primarily by the logistical and ethical constraints of taking blood samples from patients, and the statistical models that are fitted to the data...

Full description

Bibliographic Details
Main Authors: Lindegardh Niklas, Tarning Joel, Duffull Stephen B, Jamsen Kris M, White Nicholas J, Simpson Julie A
Format: Article
Language:English
Published: BMC 2011-07-01
Series:Malaria Journal
Online Access:http://www.malariajournal.com/content/10/1/181
_version_ 1818859099568209920
author Lindegardh Niklas
Tarning Joel
Duffull Stephen B
Jamsen Kris M
White Nicholas J
Simpson Julie A
author_facet Lindegardh Niklas
Tarning Joel
Duffull Stephen B
Jamsen Kris M
White Nicholas J
Simpson Julie A
author_sort Lindegardh Niklas
collection DOAJ
description <p>Abstract</p> <p>Background</p> <p>Currently, population pharmacokinetic (PK) studies of anti-malarial drugs are designed primarily by the logistical and ethical constraints of taking blood samples from patients, and the statistical models that are fitted to the data are not formally considered. This could lead to imprecise estimates of the target PK parameters, and/or designs insufficient to estimate all of the parameters. Optimal design methodology has been developed to determine blood sampling schedules that will yield precise parameter estimates within the practical constraints of sampling the study populations. In this work optimal design methods were used to determine sampling designs for typical future population PK studies of dihydroartemisinin, the principal biologically active metabolite of oral artesunate.</p> <p>Methods</p> <p>Optimal designs were derived using freely available software and were based on appropriate structural PK models from an analysis of data or the literature and key sampling constraints identified in a questionnaire sent to active malaria researchers (3-4 samples per patient, at least 15 minutes between samples). The derived optimal designs were then evaluated via simulation-estimation.</p> <p>Results</p> <p>The derived optimal sampling windows were 17 to 29 minutes, 30 to 57 minutes, 2.5 to 3.7 hours and 5.8 to 6.6 hours for non-pregnant adults; 16 to 29 minutes, 31 minutes to 1 hour, 2.0 to 3.4 hours and 5.5 to 6.6 hours for designs with non-pregnant adults and children and 35 to 59 minutes, 1.2 to 3.4 hours, 3.4 to 4.9 hours and 6.0 to 8.0 hours for pregnant women. The optimal designs resulted in acceptable precision of the PK parameters.</p> <p>Conclusions</p> <p>The proposed sampling designs in this paper are robust and efficient and should be considered in future PK studies of oral artesunate where only three or four blood samples can be collected.</p>
first_indexed 2024-12-19T09:06:48Z
format Article
id doaj.art-24c9d051e82d49488394453ce728a0ba
institution Directory Open Access Journal
issn 1475-2875
language English
last_indexed 2024-12-19T09:06:48Z
publishDate 2011-07-01
publisher BMC
record_format Article
series Malaria Journal
spelling doaj.art-24c9d051e82d49488394453ce728a0ba2022-12-21T20:28:19ZengBMCMalaria Journal1475-28752011-07-0110118110.1186/1475-2875-10-181Optimal designs for population pharmacokinetic studies of oral artesunate in patients with uncomplicated falciparum malariaLindegardh NiklasTarning JoelDuffull Stephen BJamsen Kris MWhite Nicholas JSimpson Julie A<p>Abstract</p> <p>Background</p> <p>Currently, population pharmacokinetic (PK) studies of anti-malarial drugs are designed primarily by the logistical and ethical constraints of taking blood samples from patients, and the statistical models that are fitted to the data are not formally considered. This could lead to imprecise estimates of the target PK parameters, and/or designs insufficient to estimate all of the parameters. Optimal design methodology has been developed to determine blood sampling schedules that will yield precise parameter estimates within the practical constraints of sampling the study populations. In this work optimal design methods were used to determine sampling designs for typical future population PK studies of dihydroartemisinin, the principal biologically active metabolite of oral artesunate.</p> <p>Methods</p> <p>Optimal designs were derived using freely available software and were based on appropriate structural PK models from an analysis of data or the literature and key sampling constraints identified in a questionnaire sent to active malaria researchers (3-4 samples per patient, at least 15 minutes between samples). The derived optimal designs were then evaluated via simulation-estimation.</p> <p>Results</p> <p>The derived optimal sampling windows were 17 to 29 minutes, 30 to 57 minutes, 2.5 to 3.7 hours and 5.8 to 6.6 hours for non-pregnant adults; 16 to 29 minutes, 31 minutes to 1 hour, 2.0 to 3.4 hours and 5.5 to 6.6 hours for designs with non-pregnant adults and children and 35 to 59 minutes, 1.2 to 3.4 hours, 3.4 to 4.9 hours and 6.0 to 8.0 hours for pregnant women. The optimal designs resulted in acceptable precision of the PK parameters.</p> <p>Conclusions</p> <p>The proposed sampling designs in this paper are robust and efficient and should be considered in future PK studies of oral artesunate where only three or four blood samples can be collected.</p>http://www.malariajournal.com/content/10/1/181
spellingShingle Lindegardh Niklas
Tarning Joel
Duffull Stephen B
Jamsen Kris M
White Nicholas J
Simpson Julie A
Optimal designs for population pharmacokinetic studies of oral artesunate in patients with uncomplicated falciparum malaria
Malaria Journal
title Optimal designs for population pharmacokinetic studies of oral artesunate in patients with uncomplicated falciparum malaria
title_full Optimal designs for population pharmacokinetic studies of oral artesunate in patients with uncomplicated falciparum malaria
title_fullStr Optimal designs for population pharmacokinetic studies of oral artesunate in patients with uncomplicated falciparum malaria
title_full_unstemmed Optimal designs for population pharmacokinetic studies of oral artesunate in patients with uncomplicated falciparum malaria
title_short Optimal designs for population pharmacokinetic studies of oral artesunate in patients with uncomplicated falciparum malaria
title_sort optimal designs for population pharmacokinetic studies of oral artesunate in patients with uncomplicated falciparum malaria
url http://www.malariajournal.com/content/10/1/181
work_keys_str_mv AT lindegardhniklas optimaldesignsforpopulationpharmacokineticstudiesoforalartesunateinpatientswithuncomplicatedfalciparummalaria
AT tarningjoel optimaldesignsforpopulationpharmacokineticstudiesoforalartesunateinpatientswithuncomplicatedfalciparummalaria
AT duffullstephenb optimaldesignsforpopulationpharmacokineticstudiesoforalartesunateinpatientswithuncomplicatedfalciparummalaria
AT jamsenkrism optimaldesignsforpopulationpharmacokineticstudiesoforalartesunateinpatientswithuncomplicatedfalciparummalaria
AT whitenicholasj optimaldesignsforpopulationpharmacokineticstudiesoforalartesunateinpatientswithuncomplicatedfalciparummalaria
AT simpsonjuliea optimaldesignsforpopulationpharmacokineticstudiesoforalartesunateinpatientswithuncomplicatedfalciparummalaria